Sigma Capital Management’s Puma Biotechnology PBYI Stock Holding History

Sigma Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-15,000	Closed	-$1.56M	–	74
2014 Q1	$1.56M	Sell	15,000 -5,000	-25%	-$588K	0.08%	140
2013 Q4	$2.07M	Sell	20,000 -85,000	-81%	-$4.99M	0.12%	130
2013 Q3	$5.63M	Buy	+105,000	New	+$5.66M	0.24%	115

Other funds holding PBYI

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sigma Capital Management's PBYI Position: Q2 2014 in Review

Sigma Capital Management sold out of Puma Biotechnology (PBYI) in Q2 2014, closing a stake of 15,000 shares — an estimated $1.56M sold.

Sigma Capital Management first reported a position in PBYI in Q3 2013 and held it in 3 quarters. The position peaked at $5.63M in Q3 2013. 137 funds tracked by Wall St. Rank hold PBYI as of Q2 2014.

Sigma Capital Management reported no remaining Puma Biotechnology position as of Q2 2014 after selling out during the quarter.
Sigma Capital Management sold 15,000 Puma Biotechnology shares in Q2 2014, an estimated $1.56M.
Sigma Capital Management first reported a position in Puma Biotechnology in Q3 2013 and held it in 3 quarters.
Sigma Capital Management's Puma Biotechnology position peaked at $5.63M in Q3 2013.
137 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2014.

Based on Sigma Capital Management's 13F filing for Q2 2014.